Beximco Pharmaceuticals Limited (BXP.L)

GBp 36.5

(0.0%)

Market Cap (In GBp)

162.83 Million

Revenue (In GBp)

44.39 Billion

Net Income (In GBp)

5.82 Billion

Avg. Volume

163.27 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
19.325-42.0
PE
-
EPS
-
Beta Value
0.619
ISIN
US0885792061
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mohammad Ali Nawaz
Employee Count
-
Website
https://www.beximcopharma.com
Ipo Date
2005-10-21
Details
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

More Stocks